Eris Lifesciences designates Gopal Agrawal and Nita Borkar in leadership roles

IMT News Desk
IMT News Desk
· 2 min read

The leadership roles are in the company’s flagship domestic branded formulations business

Gopal Agrawal has joined Eris as Vice President and will head up the renal care, branded injectables and market access business segments. Before joining Eris, Gopal was the Director, Market Access at Takeda.

Before Takeda, Agrawal worked with Shire and Eli Lilly. He holds a Bachelors’ degree in Science, a Masters’ degree in Electronics from Lucknow University and an MBA in Marketing from IGNOU.

Nita Borkar is the co-founder of Oaknet Healthcare and became part of the Eris organization following the acquisition of Oaknet by Eris in May 2022. She co-founded Oaknet in Apr 2015, secured private equity funding for the business and built it into a successful player in the Dermatology space before divesting it to Eris back in 2022. She has now taken on a larger role in Eris and will spearhead the dermatology, neuropsychiatry and VMN businesses. Borkar has worked with Lupin and Dabur across India, Asia Pacific and the Middle East. Nita holds a Bachelors’ degree in Microbiology and an MBA from Mumbai University.

Amit Bakshi, CMD, Eris Lifesciences said, “It is a real pleasure to have Agrawal and Borkar on board and taking on leadership roles in the business. Along with Murari who joined us last month to head the Cardiometabolic business, I am confident that our three new BU Leaders will bring their experience and expertise to bear and enable us to turbocharge the growth of our Domestic Formulations business over the next few years. I congratulate them on their new roles and wish them success.”

Read Next

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk
DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 
News
June 11, 2026

DFE Pharma earns third consecutive EcoVadis Gold Medal for sustainability performance 

DFE Pharma has earned its third consecutive Gold Medal from EcoVadis, the world leader in corporate sustainability assessments, in recognition of its strong performance in the four themes rated: Environment, Labor & Human Rights, Ethics and Sustainable Procurement. This distinction places DFE Pharma in the top 5% of companies, reflecting the company’s focused efforts to […]
Article by: IMT News Desk
Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India
News
June 11, 2026

Oval Fertility Inks MoU with Merck to Advance Reproductive Care Standards in India

Oval Advanced Fertility Care and Merck Specialities Private Limited, the Indian healthcare arm of Merck KGaA, Darmstadt, Germany and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MOU).   India’s IVF market, valued at approximately USD 2.35 billion in 2024, is projected […]
Article by: IMT News Desk
Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global
News
June 11, 2026

Infosys-backed 4baseCare raises ₹128 crore, plans to take its cancer testing platform global

Bengaluru-based precision oncology startup 4baseCare has raised ₹128 crore in its ongoing Series B funding round to expand its hospital-linked genomics laboratory network globally and scale its AI-powered precision oncology platform, OncoTwin. The latest funding round, which follows a first close of ₹90 crore co-led by Ashish Kacholia and Lashit Sanghvi with participation from existing […]
Article by: IMT News Desk